Pittsburgh Sleep Quality Index

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Retrieved on: 
Wednesday, March 6, 2024
Incidence, PSQI, Ageing, Overalls, Capital Medical University, Hospital, Sleep, Trial of the century, Pittsburgh Sleep Quality Index, Jesse Russell, Insomnia, Prevalence, TST, Fatigue, Patient, Journal, Personality disorder, SOL, Clinical trial, Pharmaceutical industry

HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.

Key Points: 
  • Key data reported from the study suggests that tACS ameliorates chronic insomnia, and that age can impact the extent of the resulting improvement from tACS treatment.
  • Older participants (ages 50 and over) experienced comparatively more significant benefits from tACS, in terms of enhanced sleep quality, efficiency and overall insomnia reduction (p
  • This is attributed to the natural changes in sleep physiology that occur with aging and the distinct manifestations of insomnia symptoms in older individuals.
  • The clinical study’s results, which were published in the Journal of Psychiatric Research, showed that tACS meaningfully reduced the severity of insomnia and enhanced sleep quality and efficiency.

Study Reveals Exciting Benefits of Using a Low Dose Valerian Extract for Sleep Quality and Occasional Anxiety

Retrieved on: 
Wednesday, November 1, 2023
Female, FACN, Pittsburgh Sleep Quality Index, Narcolepsy, Doctor of Philosophy, Research, Sleep, Male, Safety, Anxiety, Regulatory affairs, Pharmaceutical industry, Consumer electronics, Nursing, Polysomnography

The study revealed that Sleeproot significantly improved sleep quality scores based on the Pittsburgh Sleep Quality Index questionnaire, as well as:

Key Points: 
  • The study revealed that Sleeproot significantly improved sleep quality scores based on the Pittsburgh Sleep Quality Index questionnaire, as well as:
    reduced sleep latency, allowing participants to fall asleep more quickly.
  • "This study shows that Sleeproot, a low dose valerian extract, at a 2% valerenic acid potency, can significantly improve aspects of sleep quality, as measured by validated quantitative and qualitative sleep methodologies."
  • The research included regular study visits to monitor outcomes related to sleep quality and occasional anxiety.
  • Using a combination of validated sleep assessment tools, including the Pittsburgh Sleep Quality Index, Wrist Actigraphy, and Polysomnography, researchers measured various parameters of sleep quality.

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Retrieved on: 
Monday, August 7, 2023
Second Affiliated Hospital of Xinjiang Medical University, Visual analogue scale, Migraine, Depression, Prevalence, HHS, PSQI, MSQ, Clinical trial, World Health Organization, DSM-IV codes, Department of Neurology, Xuanwu hospital, Zhengzhou University, VAS, HAMA, Trial of the century, MDE, Pain, MDD, Patient, Grammatical mood, Pittsburgh Sleep Quality Index, Research, The Rheumatoid Arthritis Quality of Life Questionnaire, WHO, International Journal of Research in Marketing, Pharmaceutical industry, Brain

As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.

Key Points: 
  • As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.
  • The migraine study follows the Company’s recent clinical study in depression, which demonstrated statistically significant improvements among patients.
  • Mark White, CEO of Nexalin Technology, stated, "Research and Markets estimates the migraine and depression markets at roughly $3.9 billion and $11.2 billion, respectively.
  • We look forward to conducting additional clinical trials in new indications – many of which will be fully funded by Wider, our new JV partner.”

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

Retrieved on: 
Monday, July 10, 2023
TST, Attention deficit hyperactivity disorder predominantly inattentive, PSQI, SOL, Traumatic brain injury, Anxiety, Sleep, Mental health, Department of Neurology, Xuanwu hospital, TBI, Veteran, Insomnia, Gaylord Palms Resort & Convention Center, Trial of the century, Government, Patient, Physician, MEG, MAMP, Concussion, Poster, Capital Medical University, Laboratory, Convention center, Pittsburgh Sleep Quality Index, Brain damage, Medical imaging, Magnetoencephalography, ScienceDirect

The abstract was accepted under the breakout session: Mental Health and Traumatic Brain Injury.

Key Points: 
  • The abstract was accepted under the breakout session: Mental Health and Traumatic Brain Injury.
  • The poster for this breakout session will be presented in Poster Session 2 on Tuesday, August 15, 2023.
  • Mild traumatic brain injury (mTBI) is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • Mark White, CEO of Nexalin Technology, stated, "We are honored to announce the acceptance of our abstract regarding our non-invasive, frequency-based, deep-brain stimulation device for presentation at the highly prestigious Military Health System Research Symposium.

SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

Retrieved on: 
Tuesday, May 2, 2023
Edinburgh, CMAI, Central nervous system, Delirium, Alzheimer's disease, Pittsburgh Sleep Quality Index, Hypotension, Disease, Tolerability, Deficit spending, Falls, Appetite, Agitation, TEL, Dementia, MD, Mini–Mental State Examination, AD, Edinburgh Feeding Evaluation in Dementia Scale, Genta (company), Pharmaceutical industry, Medical imaging, Safety, Patient

TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.

Key Points: 
  • TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.
  • The Company is expecting to receive the final trial results in the upcoming weeks.
  • On November 7, 2022, the Company announced positive interim results from the open label trial, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.
  • The interim results summarize the data from the first eight patients who completed the trial as per protocol.

Nasdaq Congratulates Signifier Medical Technologies for Treating 10,000 Patients With eXciteOSA, a Daytime Therapy for Sleep Apnea

Retrieved on: 
Wednesday, March 29, 2023
General Health, Health, Other Health, Medical Devices, Heart, Critical care, Pittsburgh Sleep Quality Index, University, Clinical trial, Patient experience, Narcolepsy, Health technology, Sleep, Sleep apnea, Multimedia, OSA, Patient, Division, Epworth Sleepiness Scale, Love, Times Square, Sleep medicine, PAP, Diagnosis, FDA, Obstructive sleep apnea, Pharmaceutical industry, Medical device, AHI

Akhil Tripathi, Signifier’s co-founder and CEO said, “This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients. It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.” Signifier Medical is simplifying the complex standard of care for obstructive sleep apnea with eXciteOSA by tackling a root cause -- empowering patients to restore their nighttime breathing naturally – with a novel 20-minute daytime therapy.

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since the commercial launch in 2021.
  • Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in the heart of Times Square, New York.
  • Based on a recent study, eXciteOSA therapy demonstrates real-world adherence of more than 80% , which is exceptional in this space.
  • Signifier Medical would like to be a part of that -- transforming the standard of care for sleep apnea to help the millions of those suffering from the condition.

Insomnia Epidemiology Forecast - 2023-2032: Diagnoses Set to Increase in the Coming Years - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 16, 2023
Health, Other Health, Epidemiology, EMA, American Academy of Sleep Medicine, DMS, Sleep, Research, United Kingdom, Actigraphy, Central sleep apnea, Arousal, ISI, DSM-IV codes, Knowledge Organization (journal), PSQI, Risk, Prevalence, Fatigue, Hormone, DSM, Pittsburgh Sleep Quality Index, Patient, American Academy, Diagnosis, REM, Classification, Obstructive sleep apnea, Polysomnography, EU4, Somatization disorder, Thermoregulation, Wakefulness, Sedation, DIS, Sleep-related breathing disorder, Vaccine, Pharmaceutical industry, Nursing, Insomnia

Whereas DSM-V defines Insomnia as dissatisfaction with sleep quantity or quality, often associated with either difficulty initiating sleep or difficulty maintaining sleep.

Key Points: 
  • Whereas DSM-V defines Insomnia as dissatisfaction with sleep quantity or quality, often associated with either difficulty initiating sleep or difficulty maintaining sleep.
  • Recently, these categories were changed American Academy of Sleep Medicine categorizes insomnia into short-term insomnia, chronic insomnia, and other insomnia.
  • Other previously used subtypes now under chronic insomnia included paradoxical insomnia, idiopathic insomnia, psychophysiological insomnia, and inadequate sleep hygiene, among others.
  • The report provides the segmentation of the disease epidemiology for the 7MM, Total Diagnosed Prevalent Cases of Insomnia, Type-specific CDases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia.

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Leadership, Central nervous system, Company, Agitation, Pittsburgh Sleep Quality Index, Private Securities Litigation Reform Act, Research, Tourette syndrome, GLOBE, Hypotension, Comprehension, Autism, FDA, Memory, Apathy, Judgement, Language, Insomnia, Appetite, Dementia, Nasdaq, Cannabinoid, Neurodegeneration, Intention, CMAI, Edinburgh, Psychosis, Attention, Mini–Mental State Examination, CBD, Delirium, Edinburgh Feeding Evaluation in Dementia Scale, Annual report, U.S. Securities and Exchange Commission, Government budget balance, Medicine, Status epilepticus, THC, Tolerability, Falls, Disease, SEC, Pain, Pharmaceutical industry, Medical device, Medical imaging, Patient, Dronabinol, Alzheimer's disease, Safety

Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.

Key Points: 
  • Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.
  • This Phase IIa clinical trial is an open label study, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.
  • The interim results summarize the data from the first eight patients who completed the study as per protocol.
  • We are pleased that SCI-110 is showing clinically meaningful results and may provide a potential treatment option for Alzheimers patients with agitation, said Adi Zuloff-Shani, PhD, Chief Technology Officer of SciSparc.

Signifier Medical Technologies’ eXciteOSA®, the Only FDA-Authorized Daytime Therapy for Primary Snoring and Mild Obstructive Sleep Apnea, Demonstrates Real-World Adherence to Treatment of Over 80%

Retrieved on: 
Wednesday, September 21, 2022
FDA, Health Technology, Health, Medical Devices, Medical Affairs Bureau, Hypertension, Patient, Mask, Sleep, Research, Death, Placebo, Snoring, Company, Pittsburgh Sleep Quality Index, AHI, Obstructive sleep apnea, Continuous positive airway pressure, Health technology, Ageing, PAP, Risk, FDA, Sleep apnea, American Journal of Respiratory and Critical Care Medicine, Association, Population, Clinical trial, CPAP, Sama, Data, List of MDPI academic journals, Somnolence, Multi-Ethnic Study of Atherosclerosis, Marital status, Roy Taylor (scientist), American Journal, Epworth Sleepiness Scale, Stroke, NMES, Medicine, Mouth, Quality of life, Population health, Solution, Smoking, Multimedia, Education, Fasting, Pharmaceutical industry, Medical device, Signified and signifier, Atherosclerosis

The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.

Key Points: 
  • The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.
  • Sleep apnea is a serious condition, and adherence to treatment is both a challenge and a requirement.
  • We understand patients desire for effective treatments that fit their lifestyle, said Dr. Jessie Bakker, Executive Vice President of Medical Affairs at Signifier.
  • Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.

Interaxon Inc. (Muse®) Announces $9.5M Series C Funding Round To Expand Brain Health and Wellness Offerings

Retrieved on: 
Thursday, August 11, 2022
Consumer Electronics, Health, Other Consumer, Consumer, Technology, Other Health, Biotechnology, Muses, Meditation, EEG, Exercise, Hatch, Diet, Sleep, Industry, CEO, Population, Technology, IP, Database, Brain, Cancer, PSQI, Harvard University, University of Victoria, Research, BDC, Export Development Canada, NASA, Quality of life, Patient, Fatigue, Company, UBC, UCSD, Neurotechnology, MIT, Mayo Clinic, Mindfulness, SDK, Neuroscience, Pittsburgh Sleep Quality Index, Western University, U of T, Time, AR, VR, UCL, Mobile phone, Medical imaging, Video game console, Public relations, French Institute for Research in Computer Science and Automation

Interaxon Inc. ( Muse ), the leading consumer neurotechnology company, announced that it has closed an oversubscribed $9.5M USD Series C funding round through a non-brokered private placement.

Key Points: 
  • Interaxon Inc. ( Muse ), the leading consumer neurotechnology company, announced that it has closed an oversubscribed $9.5M USD Series C funding round through a non-brokered private placement.
  • With this funding, Interaxon aims to enrich its leading brain health platform through launching an integrated wellness membership model and further research and validation of an industry-first feature tracking longitudinal changes in the brain.
  • Interaxon will also support expanding offerings for third-party developers, researchers, clinicians and other strategic partnerships.
  • A recent discovery from Muses R&D team has showcased exciting new patterns in their extensive EEG database with strong indications of brain health.